Peer-Reviewed Article Highlights Safety and Efficacy of Low-Dose Ondansetron in Treating Alcohol Use Disorder
Adial Pharmaceuticals (ADIL), a pioneer in addiction treatment, celebrates a significant milestone with the publication of a peer-reviewed article showcasing the promising results of its lead investigational drug, AD04, in combating Alcohol Use Disorder (AUD). The study, published in the European Journal of Internal Medicine, underscores the robust safety profile and high compliance observed among patients administered AD04.
The comprehensive analysis of AD04’s liver safety profile compared to a placebo offers encouraging insights for individuals battling AUD, a condition associated with severe health risks and alcohol-associated liver disease (ALD). Notably, AD04 demonstrated no significant adverse effects and maintained liver biochemical parameters, indicating its potential as a precision treatment option.
Cary Claiborne, CEO of Adial, lauds the publication as a pivotal step towards addressing the critical needs of individuals suffering from AUD and ALD. With AD04’s outstanding safety profile and therapeutic potential, Adial Pharmaceuticals aims to revolutionize addiction treatment and improve the lives of millions worldwide.
Read original press release: here
You might like this article: The Bitcoin Halving: Insights from CEOs and its Impact on Mining Companies
